Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients.

Virus research - 1 Sept 2021

Deng Haohui, Guo Fengxia, Yu Weihua, Li Linghua, Xia Yang, Guan Yujuan, Li Jianping

Abstract excerpt

Currently, direct-acting antiviral drugs (DAAs) are widely used as therapeutic methods for hepatitis C virus (HCV)-positive patients, however, patients may experience treatment failure, and the dynamic changes of HCV genomes in these patients are unknown. In this study, three real-world DAAs cohorts were enrolled to observe clinical efficacy. In addition, serum samples from treatment failure patients at baseline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Recurrence

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 33991622
DOI: 10.1016/j.virusres.2021.198453

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients.PMID 33991622Read ↗

Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.Semantic proximity Read ↗

Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.Semantic proximity Read ↗

Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohort.Semantic proximity Read ↗

Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.Semantic proximity Read ↗

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data.Semantic proximity Read ↗

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan.Semantic proximity Read ↗

Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.Semantic proximity Read ↗

Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genomeSemantic proximity Read ↗

Whole genome sequencing of Hepatitis C virus subtype 6xa and NS5A resistance mutations in a genotype 3b relapse case after direct-acting antiviral therapy in IndiaSemantic proximity Read ↗

Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.Semantic proximity Read ↗

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Semantic proximity Read ↗

Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.